Metastasis-Directed Therapy Improves PFS in Oligometastatic Prostate Cancer
Adding MDT to intermittent hormone therapy improves disease control in oligometastatic prostate cancer, a phase 2 trial suggests.
Adding MDT to intermittent hormone therapy improves disease control in oligometastatic prostate cancer, a phase 2 trial suggests.
Artificial intelligence can predict survival in cancer patients using information from a patient’s initial consultation with an oncologist, a study suggests.